Pembrolizumab und Cetuximab als therapeutische Optionen für adenoidzystische Karzinome des Kopf-Hals-Bereiches

Schlüsselwörter

Adenoid-zystisches Karzinom - Kopf-Hals-Tumore - ex vivo - FLAVINO-Assay - Chemoresponse-Test - Pembrolizumab - Cetuximab - Immun-Checkpoint-Blockade - PD-1/PD-L1 Signalweg

Keywords

Adenoid-cystic carcinoma (ACC) - head and neck cancer - FLAVINO assay - chemoresponse test - pembrolizumab - cetuximab

^*Beide Autoren trugen gleichermaßen zu dieser Arbeit bei und teilen die Erst-Autorenschaft

^#Beide Autoren trugen gleichermaßen zu dieser Arbeit bei und teilen die Senior-Autorenschaft

Publikationsverlauf

Artikel online veröffentlicht:
19. April 2023

• Literatur

• 1 Bilroth T.. Germany: G Riemer; 1856. The Cylindroma Studies on the development of the blood vessels along with observations from the Royal University Surgical Clinic Berlin. 55-69
• 2 Bubendorf L, Feichter GE, Obermann EC. et al Pathologie – Zytopathologie.
• 3 Böcker W, Denk H, Heitz PU. et al Lehrbuch Pathologie. Elsevier Health Sciences. 2019
• 4 Martinez-Rodriguez N, Leco-Berrocal I, Rubio-Alonso L. et al Epidemiology and treatment of adenoid cystic carcinoma of the minor salivary glands: a meta-analytic study. Med Oral Patol Oral Cir Bucal 2011; 16 (07) e884-e889 DOI: 10.4317/medoral.17200.
• 5 Miglianico L, Eschwege F, Marandas P. et al Cervico-facial adenoid cystic carcinoma: study of 102 cases. Influence of radiation therapy. Int J Radiat Oncol Biol Phys 1987; 13 (05) 673-678 DOI: 10.1016/0360-3016(87)90284-7.
• 6 Hosni A, Huang SH, Goldstein D. et al Outcomes and prognostic factors for major salivary gland carcinoma following postoperative radiotherapy. Oral Oncol 2016; 54: 75-80 DOI: 10.1016/j.oraloncology.2015.11.023.
• 7 Licitra L, Cavina R, Grandi C. et al Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol 1996; 07 (06) 640-642 DOI: 10.1093/oxfordjournals.annonc.a010684.
• 8 Hill M, Constenla D, Ahern R. et al Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Oral Oncol 1997; 33 (04) 275-278
• 9 Suzuki S, Dobashi Y, Minato H. et al EGFR and HER2-Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas. Virchows Archiv 2012; 461 (03) 271-282 DOI: 10.1007/s00428-012-1282-3.
• 10 Sridharan V, Gjini E, Liao X. et al Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. Cancer Immunol Res 2016; 04 (08) 679-687 DOI: 10.1158/2326-6066.CIR-16-0031.
• 11 Hitre E, Budai B, Takacsi-Nagy Z. et al Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial. Br J Cancer 2013; 109 (05) 1117-1122 DOI: 10.1038/bjc.2013.468.
• 12 Mahmood U, Bang A, Chen YH. et al A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Int J Radiat Oncol Biol Phys 2020 DOI: 10.1016/j.ijrobp.2020.08.018
• 13 Moskaluk CA. Adenoid cystic carcinoma: clinical and molecular features. Head Neck Pathol 2013; 07 (01) 17-22 DOI: 10.1007/s12105-013-0426-3.
• 14 Azumi N, Battifora H. The cellular composition of adenoid cystic carcinoma. An immunohistochemical study 1987; 60 (07) 1589-1598 DOI: 10.1002/1097-0142(19871001)60:7 3.0.co;2L42:DASHuL42:URLEND.
• 15 Caselitz J, Schulze I, Seifert G. Adenoid cystic carcinoma of the salivary glands: an immunohistochemical study. J Oral Pathol 1986; 15 (06) 308-318 DOI: 10.1111/j.1600-0714.1986.tb00631.x.
• 16 Bell D, Roberts D, Kies M. et al Cell type-dependent biomarker expression in adenoid cystic carcinoma. Cancer 2010; 116 (24) 5749-5756 DOI: 10.1002/cncr.25541.
• 17 Da Cruz Perez DE, De Abreu Alves F, Nobuko Nishimoto I. et al Prognostic factors in head and neck adenoid cystic carcinoma. Oral Oncology 2006; 42 (02) 139-146 DOI: 10.1016/j.oraloncology.2005.06.024.
• 18 Dillon PM, Chakraborty S, Moskaluk CA. et al Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials. Head & Neck 2016; 38 (04) 620-627 DOI: 10.1002/hed.23925.
• 19 Amit M, Binenbaum Y, Trejo-Leider L. et al International collaborative validation of intraneural invasion as a prognostic marker in adenoid cystic carcinoma of the head and neck. Head & Neck 2015; 37 (07) 1038-1045 DOI: 10.1002/hed.23710.
• 20 Dietz A, Boehm A, Horn IS. et al Assay-based response evaluation in head and neck oncology: requirements for better decision making. Eur Arch Otorhinolaryngol 2010; 267 (04) 483-494 DOI: 10.1007/s00405-009-1191-5.
• 21 Chae YK, Chung SY, Davis AA. et al Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling. Oncotarget 2015; 06 (35) 37117-37134 DOI: 10.18632/oncotarget.5076.
• 22 Jagielska B, Sarnowska E, Sarnowski T. et al Contemporary diagnostic and therapeutic possibilities in patients with adenoid cystic carcinoma of the head and neck. Oncology in Clinical Practice 2020; 16 (01) 1-8
• 23 Papaspyrou G, Hoch S, Rinaldo A. et al Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review. Head Neck 2011; 33 (06) 905-911 DOI: 10.1002/hed.21458.
• 24 Lagha A, Chraiet N, Ayadi M. et al Systemic therapy in the management of metastatic or advanced salivary gland cancers. Head & Neck Oncology 2012; 04 (01) 19 DOI: 10.1016/j.oraloncology.2018.01.034.
• 25 Subramaniam T, Lennon P, O’Neill JP. Ongoing challenges in the treatment of adenoid cystic carcinoma of the head and neck. Irish Journal of Medical Science (1971 -) 2015; 184 (03) 583-590 DOI: 10.1007/s11845-015-1298-1.
• 26 Gessner K, Wichmann G, Boehm A. et al Therapeutic options for treatment of Merkel cell carcinoma. Eur Arch Otorhinolaryngol 2011; 268 (03) 443-448 DOI: 10.1007/s00405-010-1354-4.
• 27 Liu NN, Zhang SL, Chen W. The cross-contaminated cell lines of adenoid cystic carcinoma: A crucial concern. Translational Surgery 2017; 02 (01) 10-13